Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while … Farxiga was the company's second‑highest‑selling product in 2020 (after Lisinopril). The 2020 sales reflect a mix of continued growth in type‑2‑diabetes prescriptions and a rapid expansion into heart‑failure indications in several markets. Pascal Soriot, Chief Executive Officer, commented: "We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic. Highlights of the sales performance included further success in Oncology and an acceleration in the progress of Farxiga. Our pipeline also excelled, with Farxiga expanding its potential beyond diabetes and heart failure with ground … Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. Annual Sales of Farxiga reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive … /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2020. $ in millions, except per… In the U.S. Farxiga sales grew by 6% to $569 million (2019: $537 million; 2018: $591 million), partly driven by a regulatory approval in May 2020 for the treatment of patients with heart failure with reduced ejection fraction (HFrEF) in both patients with and without T2D, based on the ground-breaking DAPA-HF trial. According to the forecasts, Trulicity, an injectable diabetes medication manufactured by pharmaceutical company Eli Lilly, will have the highest sales in both 2020 and 2024 as they are estimated … Otezla* generated $617 million of sales in the fourth quarter of 2020, and $2.2 billion for the full year. Annual Sales of Dapagliflozin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Product Sales grew by 15% (11% at CER) to $7,257m, driven primarily by the performances of new medicines across Oncology and BioPharmaceuticals, including Tagrisso and Farxiga. It also provides analysis of Dapagliflozin sales forecasts, along with factors driving its market. Dapagliflozin Drug Summary Dapagliflozin, marketed as Farxiga, is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. Farxiga 2020 U.S. PROMOTIONAL AUDIT REPORT Published July 2021 • 24 Pages The 5 Key Questions Addressed by this Report: How many physicians were reached by Farxiga through reportable promotional activity in 2020 and how does this compare to its peer set in the Heart Failure, Reduce Risk of Major Cardiovascular Events, and Type 2 Diabetes – SGLT2 markets? What promotional mix was leveraged … We would like to show you a description here but the site won't allow us. Explore the FARXIGA Market trends, size, and future outlook with DelveInsight's latest report. Gain insights into Companies, emerging therapies, and forecasts Invokana (canagliflozin, Janssen) Steglatro (ertugliflozin, Merck) FARXIGA's differentiation stems from its approval in multiple indications, notably HFrEF and CKD, beyond T2DM. Revenue Performance and Sales Trends AstraZeneca reported global sales of USD 4.3 billion for FARXIGA in 2022, a 25% increase from 2021 [4]. Prescription medicine sales data for Forxiga compiled from GlobalData's pharmaceutical product revenue figures on PMLiVE's Top Pharma List. Farxiga is a close competitor in chronic kidney disease and heart failure. Because both drugs are guideline-supported, physician switching may be limited before generic substitution becomes economically compelling. What FDA regulatory approvals support Jardiance sales? Jardiance's commercial expansion followed a sequence of FDA label … CEO Pascal Soriot remarked that "2022 has started strongly for AstraZeneca," adding "Farxiga achieved $1 billion revenue in the quarter and our oncology medicines delivered product sales growth of 18% [on a constant exchange rate basis], despite COVID-19 continuing to impact cancer diagnosis and … Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Glenmark Pharmaceuticals Inc has received United States Food & Drug Administration (FDA) approval for Dapagliflozin tablets, 5 mg and 10 mg, the generic version of Farxiga tablets, 5 mg and 10 mg, of AstraZeneca AB. According to IQVIATM sales data for the 12 month period ending January 2020, the Farxiga tablets, 5mg and 10 mg market achieved annual sales of approximately $1.8 billion. Also … Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. A case in point is Farxiga dapagliflozin from AstraZeneca plc (LSE:AZN; NASDAQ:AZN), which reported 2022 sales of nearly $4.4 billion for the therapy, a 56% increase at constant exchange rates over 2021. Much of that growth can be attributed to Farxiga's expansion into new settings, with approval for heart failure with reduced ejection fraction in May 2020 and for chronic kidney disease … How many physicians were reached by Farxiga through reportable promotional activity in 2020 and how does this compare to its peer set in the Heart Failure, Reduce Risk of Major Cardiovascular Events, and Type 2 Diabetes – SGLT2 markets? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity … Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while … Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. After delivering revenue growth of 67% year-over-year, Farxiga reached $1 billion in quarterly sales for the first time during the first three months of 2022. Some drugmakers work for years to take one of their meds from launch to blockbuster status–a journey defined by competition, the market, branding and a dash of luck. But even for pharma's … In the decade since AstraZeneca's Farxiga first nabbed FDA approval to treat adults with type 2 diabetes, the drug has well surpassed blockbuster status, racking up additional indications and generating nearly $6 billion in sales in 2023. And it hasn't reached its peak yet, according to a … Farxiga (dapagliflozin) is a blockbuster diabetes medicine, and its sales track the broader SGLT2 inhibitor market. However, specific "Farxiga sales" figures (quarterly or annual revenue) aren't provided in the information available here, so I can't state exact numbers without a source. FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. (1) To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart … Much of the attention on AstraZeneca PLC in the past couple of years has focused on its blooming oncology franchise but its top earner is the pipeline-in-a-product Farxiga and sales of the SGLT2 inhibitor, which is approved type 2 diabetes, heart failure and chronic kidney disease, have soared again in the second quarter. Speaking to Scrip as the UK-headquartered giant unveiled its latest set … Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is segmented into drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD) and volume (in Units) for the above segments. Our latest results announcements and presentations include regular updates covering pipeline reports, earnings and revenue data from across the business. AstraZeneca has generated over $20.9 billion in sales revenue from Farxiga since its launch in 2014. Revenues obtained by AstraZeneca through Farxiga sales are nearly 30 times the median cost for research and development of a new drug estimated by experts. Top companies and drugs by sales in 2020 Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020 (FIG. 1a). This success came despite lower sales than 2019, as some of its biggest drugs, including multiple sclerosis treatment Ocrevus (ocrelizumab), were hit early in the pandemic owing to hospitals delaying treatments …